Low‐dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials

REFERENCES

• Cronau H, Kankanala RR, Mauger T. Diagnosis and management of red eye in primary care. Am Fam Physician 2010; 81: 137–144.
   PubMed Web of Science ®Google Scholar
• Galor A, Jeng BH. Red eye for the internist: when to treat, when to refer. Cleve Clin J Med 2008; 75: 137–144.
   PubMed Web of Science ®Google Scholar
• Dunlop AL, Wells JR. Approach to red eye for primary care practitioners. Prim Care 2015; 42: 267–284.
   PubMed Web of Science ®Google Scholar
• Abelson MB, Yamamoto GK, Allansmith MR. Effects of ocular decongestants. Arch Ophthalmol 1980; 98: 856–858.
   PubMedGoogle Scholar
• Torkildsen GL, Sanfilippo CM, Decory HH et al. Evaluation of efficacy and safety of brimonidine tartrate ophthalmic solution, 0.025% for treatment of ocular redness. Curr Eye Res 2018; 43: 43–51.
   Web of Science ®Google Scholar
• Adamczyk DT, Jaanus SD. Antiallergy drugs and decongestants. In: Bartlett JD, Jaanus SD, eds. Clinical Ocular Pharmacology, 5th ed. St Louis, MO: Butterworth‐Heinemann, 2008.
   Google Scholar
• Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 1994; 94: 134–136.
   PubMed Web of Science ®Google Scholar
• Soparkar CN, Wilhelmus KR, Koch DD et al. Acute and chronic conjunctivitis due to over‐the‐counter ophthalmic decongestants. Arch Ophthalmol 1997; 115: 34–38.
   PubMedGoogle Scholar
• Vaidyanathan S, Williamson P, Clearie K et al. Fluticasone reverses oxymetazoline‐induced tachyphylaxis of response and rebound congestion. Am J Respir Crit Care Med 2010; 182: 19–24.
   PubMed Web of Science ®Google Scholar
• Bielory L, Katelaris CH, Lightman S et al. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 2007; 9: 35.
   PubMedGoogle Scholar
• Fratelli M, De blasi A. Agonist‐induced alpha 1‐adrenergic receptor changes. Evidence for receptor sequestration. FEBS Lett 1987; 212: 149–153.
   PubMed Web of Science ®Google Scholar
• Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001; 53: 319–356.
   PubMed Web of Science ®Google Scholar
• Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open‐angle glaucoma and ocular hypertension. Drugs Aging 1998; 12: 225–241.
   PubMed Web of Science ®Google Scholar
• Fudemberg SJ, Batiste C, Katz LJ. Efficacy, safety, and current applications of brimonidine. Expert Opin Drug Saf 2008; 7: 795–799.
   PubMed Web of Science ®Google Scholar
• Rahman MQ, Ramaesh K, Montgomery DM. Brimonidine for glaucoma. Expert Opin Drug Saf 2010; 9: 483–491.
   PubMed Web of Science ®Google Scholar
• Corboz MR, Mutter JC, Rivelli MA et al. alpha2‐adrenoceptor agonists as nasal decongestants. Pulm Pharmacol Ther 2007; 20: 149–156.
   PubMed Web of Science ®Google Scholar
• Corboz MR, Rivelli MA, Mingo GG et al. Mechanism of decongestant activity of alpha 2‐adrenoceptor agonists. Pulm Pharmacol Ther 2008; 21: 449–454.
   PubMed Web of Science ®Google Scholar
• Fowler J Jr, Jackson M, Moore A et al. Efficacy and safety of once‐daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double‐blind, and vehicle‐controlled pivotal studies. J Drugs Dermatol 2013; 12: 650–656.
   PubMed Web of Science ®Google Scholar
• Tong LX, Moore AY. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea. Expert Rev Clin Pharmacol 2014; 7: 567–577.
   PubMed Web of Science ®Google Scholar
• Norden RA. Effect of prophylactic brimonidine on bleeding complications and flap adherence after laser in situ keratomileusis. J Refract Surg 2002; 18: 468–471.
   PubMed Web of Science ®Google Scholar
• Desco MC, Navea A, Ferrer E et al. Effect of prophylactic brimonidine on bleeding complications after cataract surgery. Eur J Ophthalmol 2005; 15: 228–232.
   PubMed Web of Science ®Google Scholar
• Hong S, Kim CY, Seong GJ et al. Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults. Am J Ophthalmol 2007; 144: 469–470.
   PubMed Web of Science ®Google Scholar
• Gupta A, Kekunnaya R, Sachdeva V et al. Strabismus surgery hemostasis. Ophthalmology 2012; 119: 649–650.
   Web of Science ®Google Scholar
• Pasquali TA, Aufderheide A, Brinton JP et al. Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK. J Refract Surg 2013; 29: 469–475.
   PubMed Web of Science ®Google Scholar
• Kim CS, Nam KY, Kim JY. Effect of prophylactic topical brimonidine (0.15%) administration on the development of subconjunctival hemorrhage after intravitreal injection. Retina 2011; 31: 389–392.
   PubMed Web of Science ®Google Scholar
• Dahlmann‐noor AH, Cosgrave E, Lowe S et al. Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery. J AAPOS 2009; 13: 123–126.
   PubMed Web of Science ®Google Scholar
• Derick RJ, Robin AL, Walters TR et al. Brimonidine tartrate: a one‐month dose response study. Ophthalmology 1997; 104: 131–136.
   PubMed Web of Science ®Google Scholar
• United States Department of Health and Human Services. Food and Drug Administration. Approval Package for: Lumify Ophthalmic Solution, 0.025%; 2017. [Cited 13 Aug 2018.] Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208144Orig1s0000Approv.pdf.
   Google Scholar
• Mclaurin E, Cavet ME, Gomes PJ et al. Brimonidine ophthalmic solution 0.025% for reduction of ocular redness: a randomized clinical trial. Optom Vis Sci 2018; 95: 264–271.
   PubMed Web of Science ®Google Scholar
• Gomes PJ, Ousler GW, Welch DL et al. Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy. Clin Ophthalmol 2013; 7: 157–165.
   PubMedGoogle Scholar
• Abelson MB, Gomes PJ, Vogelson CT et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double‐masked environmental study. Clin Ther 2004; 26: 1237–1248.
   PubMed Web of Science ®Google Scholar
• Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha‐2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog 2015; 62: 31–39.
   PubMedGoogle Scholar
• Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol 2008; 21: 457–461.
   PubMed Web of Science ®Google Scholar
• Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996; 41 (Suppl 1): S19–S26.
   PubMed Web of Science ®Google Scholar
• Lee DA, Gornbein J, Abrams C. The effectiveness and safety of brimonidine as mono‐, combination, or replacement therapy for patients with primary open‐angle glaucoma or ocular hypertension: a post hoc analysis of an open‐label community trial. Glaucoma Trial Study Group. J Ocul Pharmacol Ther 2000; 16: 3–18.
   PubMed Web of Science ®Google Scholar
• Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2‐adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother 2000; 1: 815–834.
   PubMedGoogle Scholar
• Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS 2001; 5: 281–284.
   PubMed Web of Science ®Google Scholar
• Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye (Lond) 2004; 18: 24–26.
   PubMed Web of Science ®Google Scholar
• Kesler A, Shemesh G, Rothkoff L et al. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size. J Cataract Refract Surg 2004; 30: 1707–1710.
   PubMed Web of Science ®Google Scholar
• Thordsen JE, Bower KS, Warren BB et al. Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes. J Cataract Refract Surg 2004; 30: 1702–1706.
   Web of Science ®Google Scholar
• Leblanc RP. Twelve‐month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998; 105: 1960–1967.
   PubMed Web of Science ®Google Scholar
• Schuman JS, Horwitz B, Choplin NT et al. A 1‐year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997; 115: 847–852.
   PubMed Web of Science ®Google Scholar
• Katz LJ. Twelve‐month evaluation of brimonidine‐purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002; 11: 119–126.
   PubMed Web of Science ®Google Scholar